Staphylococcus aureus, methicillin resistant

Antibiotic
% Susceptible
2010
% Susceptible
2012
% Susceptible
2014
% Susceptible
2016
% Susceptible
2018
Ampicillin
0
0 0 0 0
Azithromycin
-
-
-
- -
Aztreonam
-
-
-
- -
Cefazolin
0
0
0
0 0
Cefepime
-
-
-
- -
Ceftazidime
-
-
-
- -
Ceftriaxone
0
0
0
0 0
Cefuroxime
-
-
-
- -
Ciprofloxacin
21
20
22
19 18
Clarithromycin
-
-
-
- -
Clindamycin
64
73
71
73 86
Doxycycline
92
94
94
95 94
Erythromycin
5
9
9
8 8
Gentamicin
-
-
-
- -
Imipenem
-
-
-
- -
Levofloxacin 22 21 24 21 20
Meropenem - - - - -
Moxifloxacin 80 78 76 81 81
Nitrofurantoin 99& 99& 99& 96& 99&
Oxacillin/Naf 0 0 0 0 0
Penicillin 0 0 0 0 0
Piperacillin - - - - -
Piperacillin/tazo - - - - -
Ticarcillin/Clav - - - - -
Tobramycin - - - - -
TMP/SMX 97 98 98 98 100
Unasyn/Aug 0 0 0 0 0
Vancomycin 100 100 100 100 100
       
# Tested 1334 1061 1203 936 775

Comments:   38% of Staphylococcus aureus isolates in 2018 were methicillin resistant (may include duplicates).

 

Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections